Russia’s experimental cancer vaccine, Enteromix, has successfully completed preclinical trials, showing a 60–80% tumor reduction and improved survival in tested animals. Initially developed for colorectal cancer, researchers are also exploring versions for glioblastoma, melanoma, and rare ocular melanoma. While some reports claim 100% effectiveness, verification remains pending. The vaccine is “ready for use” pending government approval, but no timeline for human trials or widespread availability has been announced. Experts see it as a potential breakthrough in cancer treatment.
-68c2ca6261171.jpg)
Russia has announced that its experimental cancer vaccine, Enteromix, has successfully completed preclinical trials. Researchers express optimism that this development could open new avenues in treating life-threatening diseases like cancer.
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
